Alan F. Denenberg

Davis Polk advised the representatives of the several underwriters in connection with the $1.3 billion initial public offering of 39,807,691 shares of Class A common stock of GoodRx…

Davis Polk is advising CrowdStrike Holdings, Inc. in connection with its acquisition of Preempt Security, Inc., a leading provider of Zero Trust and conditional access technology for real…

Davis Polk advised the representative of the initial purchasers in connection with a Rule 144A offering by The Marcus Corporation of $100.05 million aggregate principal amount of its 5…

Davis Polk advised the representatives of the several underwriters in connection with the $325.6 million initial public offering of 14,800,000 shares of common stock of Sumo Logic, Inc…

Davis Polk advised the representatives of the initial purchasers in connection with a Rule 144A offering by Medallia, Inc. of $575 million aggregate principal amount of its 0.125%…

Davis Polk advised the representative of the initial purchasers in connection with a Rule 144A/Regulation S offering by Uber Technologies, Inc. of $500 million aggregate principal…

Davis Polk advised the representatives of the several underwriters in connection with the follow-on offering of 4,791,665 shares of common stock of Natera, Inc. for total gross…

Davis Polk advised the underwriters in connection with the initial public offering of 30,000,000 units of Prime Impact Acquisition I, for aggregate proceeds of $300 million. Each unit…

Davis Polk advised the joint book-running managers in connection with an SEC-registered offering by Globe Life Inc. of $50 million aggregate principal amount of 2.150% senior notes due 2030…

Davis Polk is advising JP Morgan Securities LLC and Lazard as financial advisers to Aimmune Therapeutics in connection with its $2.6 billion sale to Sociétés des Produits Nestlé, S.A., a…